Physician profile
Sarah Haydel
NPI 1811965932
$264,617.87
in general payments reported to CMS, 2019-2025
41 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $24K · 2021: $44K · 2022: $24K · 2023: $38K · 2024: $38K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Food and Beverage: $10K · Travel and Lodging: $1,772 · Consulting Fee: $1,650 · Education: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,853.88 |
| Food and Beverage | $10,086.82 |
| Travel and Lodging | $1,772.25 |
| Consulting Fee | $1,650.00 |
| Education | $426.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232,107.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $11,874.99 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $5,948.99 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $2,615.71 | 2019-2025 | Tremfya |
| Medimetriks Pharmaceuticals, INC. | $1,567.15 | 2019-2025 | Clindacin Etz, Neo-Synalar |
| Lilly USA, LLC | $1,154.09 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $1,036.66 | 2019-2025 | |
| Genzyme Corporation | $856.46 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $851.39 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $752.06 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $667.51 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $545.14 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $500.09 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $464.69 | 2022-2025 | Opzelura |
| Almirall LLC | $438.63 | 2019-2025 | Klisyri, Seysara |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Haydel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.